Gradient-Echo Spectroscopic Imaging Study of Saturated Fat and Breast Cancer

Status: Recruiting
Location: See location...
Intervention Type: Diagnostic test
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The role of fat in breast cancer development and growth has been studied extensively using body mass index, a measure of whole body fatness, and dietary fat intake in a number of epidemiological studies. However, there is a paucity of studies, on an individual level, to assess the role of breast fat itself in breast cancer due to lack of a non-invasive and fast measurement method. Since breast fibroglandular cells are surrounded by breast fat cells, the characteristics of breast fat may have a stronger relationship with breast cancer development, as supported by recent studies showing that a majority of breast cancer develops at the interface between fibroglandular tissue and adipose tissue. However, it is not trivial to study the role of breast fat, mainly due to the lack of a non-invasive and fast measurement method sensitive enough to important features of breast fat, such as types of fat.Recently, we have developed a rapid MRI method, referred to as Gradient-echo Spectroscopic Imaging (GSI), to measure fatty acid composition during clinical breast MRI exams. GSI can provide map of saturated fat and unsaturated fats in the breast adipose tissue without performing tissue biopsy. Our pilot study found that the postmenopausal women with aggressive breast cancer, known as invasive ductal carcinoma, have a significantly higher percentage of saturated fat in their breast adipose tissue than the postmenopausal women with only benign lesions.

Eligibility
Participation Requirements
Sex: Female
Minimum Age: 25
Maximum Age: 99
Healthy Volunteers: t
View:

• No contraindications to MRI scanning (pacemaker, implanted metallic objects, severe obesity or other condition that leads to difficulty lying in the magnet)

• No contraindication to gadolinium contrast agent (severe renal insufficiency (EGFR\<30), allergy to gadolinium) which will be injected for clinical exam

• Able and willing to provide informed consent

• Post-menopausal age \> 25 years.

Locations
United States
New York
NYU Langone Health
RECRUITING
New York
Contact Information
Primary
Reshma Gadde
Resma.Gadde@nyulangone.org
6465014320
Backup
Samuel Brazil
samuel.braziel@nyulangone.org
6465012540
Time Frame
Start Date: 2018-07-23
Estimated Completion Date: 2025-04-17
Participants
Target number of participants: 135
Treatments
Active_comparator: Breast cancer confirmed by biopsy
Cases will be women first diagnosed with invasive breast cancer confirmed by biopsy
Active_comparator: Women without any history of breast cancer
No known malignancy confirmed by at least 1-year follow up exams.
Related Therapeutic Areas
Sponsors
Leads: NYU Langone Health

This content was sourced from clinicaltrials.gov